fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Azelaic acid

All products: general benefit

Finacea · DIN 02270811 · 15% · Top Gel

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
No interchangeable product listed in the Ontario extract
Finacea · DIN 02270811 Manufacturer: Leo Pharma Inc.; listing date 2011-09-15 Health Canada: Marketed since 2020-04-16 · brand FINACEA · ATC D10AX03 AZELAIC ACID · form Gel · route Topical · ingredients AZELAIC ACID 15 %/W/W · company Leo pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Finacea: Formulary list price $0.88 per unit (the source does not state the unit; exact figure $0.8763). What the ministry pays, not the patient.

Ministry pays: $0.8763 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02270811)

Source record
DIN 02270811: Finacea Raw flags: sec3=Y Item: 843600091; group id 857; item number 2078; lccId None; manufacturer id LEO Source form: Top Gel; strength: 15% Recorded listing: General benefit Source prices (unrounded): $0.8763; ministry $0.8763 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02270811 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75617
Shortage status: resolved shortage (ended April 16, 2020); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02270811
Shortage record checked October 6, 2026

Other products in the same Health Canada class (D10A): coverage varies; not interchangeable

  • Adapalene + benzoyl peroxide (TactuPump Forte): not a benefit
Other drugs in the same formulary class (84:36 Miscellaneous Skin and Mucous Membrane Agents) and how they are covered

Matched class: 84:36 Miscellaneous Skin and Mucous Membrane Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ACITRETIN, FLUOROURACIL, ISOTRETINOIN, ZINC SULFATE Some products covered without a code (check the product listing): COLLAGENASE 84:36 Miscellaneous Skin and Mucous Membrane Agents

ADAPALENE & BENZOYL PEROXIDE

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 0.3% w/w & 2.5% w/w · Top Gel

ACITRETIN

· 6 products · General benefit · strengths: 10mg, 25mg · Cap

COLLAGENASE

· 2 products · General benefit (1), Temporary benefit (1) · strengths: 250Unit/g · 30g Pk, Oint-30g Pk

FLUOROURACIL

· 1 products · General benefit · strengths: 5% · Cr

ISOTRETINOIN

· 8 products · General benefit · strengths: 10mg, 20mg, 30mg, 40mg · Cap

ZINC SULFATE

· 2 products · General benefit · strengths: 0.5%, 10mg · Oint, Sup

ALITRETINOIN

· 4 products · Listed, not a benefit (2), Limited Use, codes 442 (2) · strengths: 10mg, 30mg · Cap

BRODALUMAB

· 1 products · Limited Use, codes 553 · strengths: 210mg/1.5mL · Inj Sol-Pref Syr

CALCIPOTRIOL

· 1 products · Limited Use, codes 191 · strengths: 50mcg/g · Oint

CALCITRIOL

· 1 products · Limited Use, codes 191 · strengths: 3mcg/g · Oint

IXEKIZUMAB

· 2 products · Limited Use, codes 526 · strengths: 80mg/mL · Inj Sol-Pref Autoinj, Inj Sol-Pref Syr

PIMECROLIMUS

· 1 products · Limited Use, codes 383 · strengths: 1% · Cr Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 84:36 and 3 more
Full class listing Related classes: 84:04 Anti-Infectives, 84:06 Anti-Inflammatory, 84:28 Keratolytic Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications FINACEA (azelaic acid) is indicated for: • Topical treatment of inflammatory papules and pustules and erythema of mild to moderate rosacea. 1.1. Pediatrics Pediatrics (<18 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of FINACEA in pediatric patients have not been established; therefore, Health Canada has not authorized an indication for pediatric use (see 7 Warnings and Precautions). 1.2. Geriatrics Geriatrics (> 65 years of age): Clinical studies of FINACEA did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently than younger subjects (see 7 Warnings and Precautions). https://pdf.hres.ca/dpd_pm/00083784.PDF PM date: not printed or not captured Source product: FINACEA; DIN 02270811; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.